Literature DB >> 20573573

The different performance among motor tasks during the increasing current intensity of deep brain stimulation of the subthalamic nucleus in rats with different degrees of the unilateral striatal lesion.

Xin Fang1, Kenji Sugiyama, Soichi Akamine, Wei Sun, Hiroki Namba.   

Abstract

Of all the parameters in the deep brain stimulation (DBS) of the subthalamic nucleus (STN) in the Parkinson disease (PD) animal models, the selection of the stimulation current intensity is alterable and argumentative to affect the stimulation charge or charge density. In order to observe the different performances among several motor tasks during the STN-DBS in rats, we observed the behavioral performance during the stimulation with 0, 100, 150 and 200microA currents. We found that the DBS efficacy reached the climax during the 200microA stimulation at the methamphetamine-induced rotational behavioral test, however at the stepping test and rotarod test, the critical current were 150microA to reach the best improvements. Such findings suggest that the stimulation parameters to reach the climax efficacy among the different symptoms are different during the STN-DBS experiments in rats. The appropriate stimulation parameters should be selected by the symptoms separately according to the aim of each study. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573573     DOI: 10.1016/j.neulet.2010.06.004

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Authors:  Seong-Jin Yu; Mikko Airavaara; Hui Shen; Jenny Chou; Brandon K Harvey; Yun Wang
Journal:  Psychopharmacology (Berl)       Date:  2011-12-13       Impact factor: 4.530

Review 2.  Peripheral stimulation in treating Parkinson's disease: Is it a realistic idea or a romantic whimsicality?

Authors:  Tetsuya Asakawa; Huan Fang; Zhen Hong; Kenji Sugiyama; Takao Nozaki; Hiroki Namba
Journal:  Intractable Rare Dis Res       Date:  2012-11

Review 3.  Role of Parameter Setting in Electroacupuncture: Current Scenario and Future Prospects.

Authors:  Yuan-Yuan Zhang; Qi-Liang Chen; Qiong Wang; Shan-Shan Ding; Shu-Nan Li; Shu-Jiao Chen; Xue-Juan Lin; Can-Dong Li; Tetsuya Asakawa
Journal:  Chin J Integr Med       Date:  2020-07-20       Impact factor: 2.626

4.  Deep Brain Stimulation of Hemiparkinsonian Rats with Unipolar and Bipolar Electrodes for up to 6 Weeks: Behavioral Testing of Freely Moving Animals.

Authors:  Kathrin Badstuebner; Ulrike Gimsa; Immo Weber; Armin Tuchscherer; Jan Gimsa
Journal:  Parkinsons Dis       Date:  2017-07-03

5.  Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.

Authors:  Veronica A Antipova; Carsten Holzmann; Oliver Schmitt; Andreas Wree; Alexander Hawlitschka
Journal:  Front Behav Neurosci       Date:  2017-06-21       Impact factor: 3.558

6.  Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms.

Authors:  Sébastien Valverde; Marie Vandecasteele; Charlotte Piette; Willy Derousseaux; Giuseppe Gangarossa; Asier Aristieta Arbelaiz; Jonathan Touboul; Bertrand Degos; Laurent Venance
Journal:  Nat Commun       Date:  2020-05-13       Impact factor: 14.919

7.  Rat subthalamic stimulation: Evaluating stimulation-induced dyskinesias, choosing stimulation currents and evaluating the anti-akinetic effect in the cylinder test.

Authors:  Antti Huotarinen; Sakari Leino; Raimo K Tuominen; Aki Laakso
Journal:  MethodsX       Date:  2019-10-14

8.  Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Authors:  Veronica Antipova; Carsten Holzmann; Alexander Hawlitschka; Martin Witt; Andreas Wree
Journal:  Toxins (Basel)       Date:  2021-07-20       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.